Abstract. By analogy with the problem of evaluating the genetic risks of radiation, it appears that it will be extremely difficult to assess the mutagenicity for man of the wide range of chemicals to which human populations are currently exposed. Nevertheless, the potential significance of this problem calls for a major effort at such an evaluation.
One of the recurring themes in any consideration of environmental pollution, whether by chemicals or radiation, has been the question of the genetic dangers involved. Although by invitation I am to speak on the problem of chemical mutagenesis in man, in fact most of these remarks will, for three reasons, be concerned with radiation mutagenesis. Firstly, the two subjects are conceptually almost inextricably interrelated. Secondly, the very same problems that have arisen in trying to understand the genetic threat of increased radiation exposures will arise with respect to trace chemicals-not to mention a few new ones. There is much to be said for viewing the potential threat of chemical mutagenesis from the perspective of 40 years of radiation genetics. Thirdly, such is our ignorance of chemical mutagenesis in man or any other mammal that it is difficult to find hard data to sustain even as brief a presentation as this.
The thesis of this presentation will be that while there seems no immediate danger of massive genetic damage from the trace chemicals, i.e., no genetic catastrophe, it does seem quite possible that current exposures to trace chemicals have increased human mutation rates. Since mutations are thought to have deleterious effects rather more often than beneficial effects, this increase is to the detriment of man. Unfortunately, it seems impossible to maintain the levels of energy production and food consumption on which our culture is based without some increased exposure to mutagenic agents. Accordingly, unless we are prepared to forego many aspects of our present culture and at the same time drastically reduce population numbers, we shall probably have to live in the foreseeable future with some increase in mutation rates. We are thus confronted with the problem of striking the best balance possible between genetic damage and the benefits our culture has thus far shown no signs of abandoning, and to do this intelligently we must collect the necessary information. It is not now at hand.
The quantitation of genetic damage: It is impossible in the brief time available to begin to do justice to the vast literature on experimental mutagenesis.
The bulk of this literature deals with bacteria, fungi, protozoa, a variety of insects, and many plants, but there is an accumulating body of knowledge on mammals, to which these remarks will be restricted. There are in general two approaches to measuring induced genetic damage. One, to be termed the "specific locus approach," attempts to measure mutation at specific genetic loci. This approach, thus far limited among mammals to the house mouse, permits very precise measurements of mutation at certain loci, but then depends on somewhat dubious assumptions concerning the number of genes and the manner in which the average mutation expresses itself, for estimates of the actual harm suffered by populations. The second approach, to be termed the "population characteristics approach," bases the case on the effects of a mutagen on such complex but important aspects of the study population as the frequency of congenital malformations, survival rates from fertilization onwards, sex ratio, physical growth and development, and fertility. Each of these latter indicators is undoubtedly influenced by mutation at many different loci, as well as by environmental variables, so that careful consideration of environmental factors is essential, and simple genetic explanations of positive findings unlikely. However, there is little room for debate about the significance for a population of a definite finding with respect to one of these indicators.
The two approaches should be thought of as complementary rather than competing, with, ultimately, each one illuminating the results of the other. With either of these approaches, it has been convenient to use the "doubling dose" as a reference point. This is the amount of radiation or chemical exposure which would result in a mutation rate twice the "normal" spontaneous rate, or which would double the genetic contribution to congenital malformations or early death rate. Inasmuch as we have some knowledge of the contribution of spontaneous mutation to human morbidity and mortality, some geneticists, including myself, feel that the calculation of a doubling dose provides an important frame of reference.
The complexity of assessing the effects of a mutagen, as illustrated by developments in mammalian radiation genetics: The extensive work on radiation mutagenesis in small animals, especially the mouse, now provides many evidences of the potential complexity of the chemical mutagenesis problem. With respect to the specific locus approach, the early studies on the mouse, concerned with the genetic yield from spermatogonia receiving large doses of radiation over a short period of time, resulted in estimates of the probability of mutation per locus per R unit of approximately 0.6 X 10-7 (Harwell data) or 2.2 X 10-7 (Oak Ridge data). Estimates of the yield from irradiated oocytes fertilized shortly following the radiation treatment were slightly higher. The spontaneous rate of mutation per locus per generation in male mice is about 0.8 X 10-5. The amount of radiation of this type necessary to increase the mutation rate to twice its spontaneous value (i.e., the doubling dose) would thus be about R. '12 However, short of nuclear catastrophe, our species will not receive most of its radiation in this manner. Rather, the exposures (above background) of both sexes will usually be small, intermittent, and/or at low dose rates, and progeny will often be conceived at long intervals following the radiation. There have been two important developments that indicate that under these circumstances, the doubling dose will be considerably higher. Firstly, there are dose rate and dose fractionation effects. With respect to spermatogonia, a dose rate of 0.009 R/min produced only about one quarter as many specific locus mutations as were induced by a dose rate of 90 R/min.' '3 There is a similar dose rate effect in females. Indeed, in oocytes receiving a dose of 400 R at the rate of 0.009 R/min, the mutation rate was not significantly elevated.4'5 Fractionation of a given dose of radiation also results in a lower yield of mutations than administration of the total dose in one exposure.6 Secondly, although in the case of spermatogonia the yield appears to be essentially the same no matter whether progeny tests are conducted shortly after radiation or a year later, in the female it is quite different. Thus, whereas an increased mutation rate was readily demonstrated in the progeny of female mice receiving 50 R at the rate of 90 R/min when those progeny were conceived within 6 weeks of radiation, progeny conceived later demonstrated no increase in the mutation rate. These findings in my opinion clearly suggest that given the human reproductive pattern, the doubling dose of radiation as received from industry and medicine is not likely to be less than 200 R.
With respect to the "population characteristics" approach, in addition to the mouse, rather extensive data are now available for the rat, pig and man. As regards man, our own studies on children born to the survivors of the atomic bombings of Hiroshima and Nagasaki reveal no effect of the exposure on stillbirth rate, frequency of congenital malformation, birthweight, death during infancy and childhood, or rate of physical growth and development.78 An apparent effect on sex ratio in the early years of the study was not borne out in the later years.9 Incidentally, the other investigations of a possible sex-ratio effect in man have with impressive consistency yielded results similar to those of the early years in Hiroshima and Nagasaki (reviewed in refs. 10 and 11). On admittedly tenuous grounds we have suggested that for man the "doubling dose" of radiation of the Hiroshima-Nagasaki acute, high dose-rate type is probably not less than 50 R,8 an estimate in satisfactory agreement with the estimate of R derived from mice for the same type of radiation.
There are now much better, controlled observations on experimental mammals than those on man, involving large cumulative doses over several generations. In both the mouse and rat, autosomal recessive lethal effects from acute spermatogonial irradiation occur with a frequency of approximately 1 X 10-4 per gamete per R. Dominant lethal effects, resulting in the death of the animal in the first post-radiation generation and so quickly eliminated, have about the same frequency (reviewed in ref. 12) . Surprisingly, net dominant heritable damage has not been observed, i.e., there is no evidence for induced dominant detrimental mutations, thought to be relatively frequent in Drosophila (reviewed in ref. 13 ). Taylor and Chapman'4 find the over-all rates of mutation to recessive lethal effects and visible mutants in rats to be lower than anticipated from estimates based on the specific-locus rate studies in the mouse. The now-extensive swine data reveal that 300 R of spermatogonial radiation has a significant positive effect on litter size in one of the two breeds studied, and no effect on post-natal mortality.'5 Thus, these studies tend to suggest that the doubling dose for the en-tire genome is greater rather than less than the above quoted figures based on specific-locus studies.
Simultaneously with the accumulation of the foregoing data, there have been two important conceptual developments. During much of the past 20 years, a prevailing viewpoint, most readily associated with the writings of Muller, has been that the mutations produced by radiation were except in very rare instances harmful, and that each harmful mutation eventually resulted in one genetic death. However, as we emphasized some years ago,'6 selection is directed towards the total phenotype rather than a specific locus, so that the death of a single particularly unfortunate individual might remove from the population a number of deleterious mutants. Recently this concept, of threshold effects in selection, has been greatly refined mathematically;'7-'9 clearly under this assumption the cost of increased mutation rates in individual mortality and morbidity is not as great as under earlier formulations. Furthermore, serious doubts are being raised as to whether the proportion of mutations which are deleterious is as high as previously assumed.20I -22 There 40 years of active, imaginative, and extensive work on the mutagenic effects of radiation-an agent whose tissue dose can be precisely quantitated-we are still many steps removed from the ability to predict pre-cisely the biologically significant results of human exposure, with public concern over any exposure still running high.
The study of chemical mutagenesis in mammals, including man: There is of course a very extensive literature on chemical mutagenesis in a variety of organisms ranging from viruses to Drosophila, and it is out of the finding that literally dozens of chemicals demonstrably mutagenic in these organisms are now present in the human environment that the present concern for the risks to man springs. I will not stop to enumerate the usual litany of potential offenders, ranging from well-known pesticides and herbicides to antibiotics and other medications.31-33 Mammalian experimentation with chemical mutagens is largely limited to the past decade; there is a paucity of data. Most of the observations involve the induction of dominant lethals in the mouse or rat, these defined as dominant genetic changes incompatible with survival of the conceptus (whose "dominance," paradoxically, thus cannot be analyzed in the usual genetic sense). Some of the problems in mutagenicity tests of this type have been reviewed by Rohrborn.34 Much of the early work involved a variety of alkylating agents, especially the alkanesulphonic esters, but such other compounds as aflatoxin, trimethylphosphate, and benzo(a)-pyrene have also been found to be mutagenic in mice (reviews in refs. [35] [36] [37] [38] [39] [40] . These are potent mutagens in lower organisms. Caffeine, a weaker mutagen, has not yet been shown to increase the frequency of dominant lethals in mice (review in ref. 41) , and at the moment stands as an example of the difficulties in extrapolating from lower organisms to mammals.
Most geneticists experience great difficulty in projecting from dominant lethals to effects on populations. The more laborious demonstration of the production of specific locus mutations is just getting under way, Cattanach42'43 having shown that triethylene melamine increases the frequency of point mutations in the mouse. While the choice of this particular chemical was probably dictated by its known effectiveness in other experimental material, humans receiving this or other cytostatic agents therapeutically seldom reproduce subsequently44; from the standpoint of human implications, an urgent problem is to identify just which mutagens should be given priority in investigation. Strain and sex variation has already been demonstrated in the sensitivity of mice to dominant lethal induction with triethylene melamine, 2,3,5-tri(ethylene-imino)-p-benzoquinone (Trenimon), and ethyl methanesulfonate,4547 indicating the complexity of what is to come. Thus far the routes of administration have usually been intraperitoneal, and there is to my knowledge no evidence for the mutagenic effects of chemicals administered through physiological portals, either gastrointestinal or respiratory. The problem of estimating gonad doses of both a drug and its possibly mutagenic metabolites has been discussed by Goldstein.32 Since the structures of the various chemical mutagens differ widely, it would appear unwise to extrapolate from one to another. Ideally, the effect of each agent in physiological doses should be studied as carefully as radiation. But we have just seen how many uncertainties still persist for radiation itself. The necessary evaluations demand a major effort. Under the circumstances, there is an urgent need for reliable shortcuts and screening procedures. Currently there is a very lively interest in the possibility that one can screen the known chemical mutagens for their mutagenicity in the intact animal by their effectiveness in causing chromosomal damage or inducing somatic mutation in tissue culture material (discussion in refs. 40 and 49) . However, while I count myself an enthusiastic supporter of these various screening methods, I do believe that as a basis for formulating policy concerning human exposures there is absolutely no substitute for data on the ability of potential chemical mutagens to induce heritable changes in proteins and physiologically important traits in intact organisms, preferably man.
I would like to close this presentation with what must be labeled a "typical genetic utterance." Man's most precious possession is his genetic endowment. Each generation holds it in trust for subsequent generations. As we struggle to move towards those new levels of social and technological organization which will enable us to meet the kinds of problems we have been discussing in this symposium, surely an important element in the decision-making process must be knowledge of the genetic cost. At the outset, I voiced optimism that the chemical mutagens posed no threat of massive genetic damage. This viewpoint was based on rough extrapolations from experimental material, but I would be hardpressed for a rigorous documentation. For instance, with the exception of caffeine,32 I have been unable to find any data concerning the accumulation in the human gonad of potential mutagens following exposure. Furthermore, the questions of possible synergism of different chemicals and of cumulative effects in long-lived animals is largely unexplored.
There have been several recent discussions of the various approaches to monitoring human populations for increased mutation rates from chemical exposures.33,40,U,49 In my opinion, recent technical developments in our ability to detect variant proteins by the relatively cheap techniques of electrophoresis set the stage for the much more effective monitoring of human populations than in the past. A single blood specimen permits the inspection of at least 20 and possibly 30 different proteins for evidences of mutational damage. If 100,000 blood specimens from the umbilical cords of newborn infants were monitored for 20 proteins each year, and if the spontaneous rate of mutation is 1 X 10-5, then an increase from an observed 20 mutants in 2,000,000 determinations to 35 in a similar number (or decrease to 9) would be significant at the 5% level. If one assumed the lower figure provided a "baseline" estimate, then one could detect under these circumstances a 72.5% increase in mutation rates. More sensitive detection systems (and most would feel the foregoing to be minimal) can be achieved simply by increasing sample size. Such studies could be combined with a search for an increase in chromosomal abnormalities. This approach has the advantage that the investigator can select important target proteins, rather than (as with the specific locus approach in the mouse) being forced to utilize genetic loci known to us by virtue of mutations with clear phenotypic effectswhich may be nonrepresentative for that very reason.
The practical difficulties-and there are some-do not appear insuperable. Should a significant increase in genetically abnormal proteins be detected, we are of course confronted with the problems of translating this kind of information into relevance to morbidity and mortality, as mentioned earlier. In the case of the chemical mutagens, we also face the issue of identifying which of many possible offenders is at fault. But if there is no evidence of increased damage, we will have substantially lessened one of the major concerns of a large sector of the biomedical community. As for the cost to the United States-it is nothing beside the cost of a year's logistical support for Viet Nam or even one supersonic transport. Finally, let me reiterate the opening statement: in order to support our technology we may have to compromise with the desire of the geneticist for no increase in mutation rates-but we owe it to our offspring to see that the compromise is based on knowledge rather than a guess we may later regret.
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